Novitas Solutions, Inc. has issued its final Local Coverage Determination (LCD) for Medicare payments for the 4Kscore® test with defined coverage criteria, effective December 30, 2019.The 4Kscore® Test is used in men after an abnormal prostate-specific antigen (PSA) or digital rectal exam (DRE) result. It provides the risk offinding high-grade prostate cancer if biopsy were to be performed and has the potential to minimize avoidable biopsy procedures, reducingcosts associated with identifying and treating prostate cancer. The goal for prostate cancer early detection should be to avoid over-diagnosisand over-treatment, which happens when an abnormal PSA leads directly to a prostate biopsy, but also to avoid under-diagnosis and delayedtreatment of aggressive cancers due to reduced testing.